Survival of idiopathic pulmonary fibrosis patients treated with antifibrotics versus lung transplantation
Abstract
To retrospectively analyze, if idiopathic pulmonary fibrosis (IPF) patients under 65 years at diagnosis, who fulfill criteria for LTx listing, profit from antifibrotic treatment or LTx (assessed with survival).